Urinary PABA recovery after oral N-benzoyl-L-tyrosyl-PABA administration combined with various exocrine pancreatic stimulants.
Eleven healthy volunteers (C) and nine patients affected by chronic relapsing pancreatitis (CP) were administered N-Benzoyl-L-Tyrosyl-PABA orally, at a dose of 150 mg combined, on different days, with: 1) water alone (schedule a); 2) Lundh meal (schedule b); 3) Secretin-Caerulein by i.v. infusion (0.5 CU/kg/hr and 75 ng/kg/hr respectively) (schedule c); 4) Caerulein by i.m. injection (300 ng/kg) (schedule d). The mean urinary PABA recovery in CP was lower than in C with all the schedules, but this was statistically significant only with schedules a and c (P less than 0.02 and P less than 0.05 respectively). With respect to b, c, and d, the mean urinary PABA recovery seemed to increase both in C and in CP as compared with schedule a, but only in the CP group with schedule b was the increase statistically significant (P less than 0.05). The present data show that the exocrine pancreatic stimulants do not improve the reliability of the PABA test.
D010129:4-Aminobenzoic Acid / Q000652:urine; D062365:Aminobenzoates; D002108:Ceruletide / Q000008:administration & dosage*; D002908:Chronic Disease; D006801:Humans; D007263:Infusions, Parenteral; D007273:Injections, Intramuscular; D010195:Pancreatitis / Q000175:diagnosis* / Q000652:urine; D012633:Secretin / Q000008:administration & dosage*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000652:urine; D014867:Water; D062366:para-Aminobenzoates
D062365:Aminobenzoates; D062366:para-Aminobenzoates; D014867:Water; D012633:Secretin; C006717:bentiromide; D014443:Tyrosine; D002108:Ceruletide; D010129:4-Aminobenzoic Acid